Preparing for Regulatory Review and Reimbursement DecisionsA Case for Cooperation between Regulatory Authorities, Sponsors and Health Technology Assessment Agencies

被引：0

|

作者：

Lawrence E. Liberti

Franz Pichler

Stuart R. Walker

机构：

[1] The Johnson Building,CMR International Institute for Regulatory Science

来源：

Pharmaceutical Medicine | 2009年 / 23卷 / 5-6期

关键词：

D O I：

10.1007/BF03256778

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：263 / 267

页数：4

相关论文

共 24 条

[21] The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison acro ss regulatory and health technology assessment agencies
Sarri, Grammati
Hernandez, Luis G.
[J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (09)
[22] Collaborative procedure between the World Health Organization Prequalification of Medicines Programme and national medicines regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products
[J]. WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2013, 981 : 155 - 188
[23] INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER) VS. HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES: THE CASE OF MULTIPLE MYELOMA AND PCSK9S
Jaksa, A.
Liden, D.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A494 - A494
[24] A Review of the Use of EQ-5D for Clinical Outcome Assessment in Health Technology Assessment, Regulatory Claims, and Published Literature( Dec, 10.1007/s40271-023-00662-7, 2023)
Shaw, Caroline
Longworth, Louise
Bennett, Bryan
McEntee-Richardson, Louise
Shaw, James W.
[J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2024, 17 (03): : 251 - 251